Home
Live Updates
VBI Vaccines Reports Third Quarter 2023 Financial Results : comparemela.com
VBI Vaccines Reports Third Quarter 2023 Financial Results
PreHevbrio global net revenue increased 52% quarter-over-quarter from Q2 to Q3 2023
Continued execution across earlier-stage pipeline, including:
Initiation of Phase 2b study of VBI-1901 in...
Related Keywords
Wuhan ,
Hubei ,
China ,
Cambridge ,
Cambridgeshire ,
United Kingdom ,
United States ,
Gilboa ,
Ha Afon ,
Israel ,
Rehovot ,
Hamerkaz ,
Japan ,
Ottawa ,
Ontario ,
Canada ,
Massachusetts ,
Canadian ,
Israeli ,
Brii Biosciences Bio ,
Jeff Baxter ,
Prehevbrio Prehevbri ,
Brii Bio ,
European Union Economic Area ,
Delivery Networks Idns ,
Association With ,
Nasdaq ,
Reconciliations Of The Company ,
Key Program Achievements ,
Coalition For Epidemic Preparedness Innovations ,
Foreign Exchange Loss ,
Vaccines Inc ,
Technology Platform ,
Company Quarterly Reports On Form ,
European Union ,
Agenus Inc ,
Projected Upcoming ,
Integrated Delivery Networks ,
Brii Biosciences ,
Asia Pacific ,
Expert Review ,
Liver Meeting ,
Orphan Drug Designated ,
Individualized Screening Trial ,
Innovative Glioblastoma Therapy ,
Multivalent Pan Coronavirus Vaccine ,
Epidemic Preparedness Innovations ,
Cash Used ,
Operating Activities ,
Net Loss Per Share ,
Excluding Impairment Charges ,
Canadian Dollars ,
New Israeli Shekel ,
Net Loss ,
Foreign Exchange ,
Months Ended September ,
European Economic Area ,
Safety Information ,
Full Prescribing ,
Immune Response After ,
Private Securities Litigation Reform Act ,
Nasdaq Capital Market ,
Annual Report ,
Quarterly Reports ,
Consolidated Statement ,
Thousands Except Share ,
Per Share Amounts ,
Loss Available ,
Markets ,
comparemela.com © 2020. All Rights Reserved.